两药联合治疗慢性肺源性心脏病急性加重期临床研究

Clinical research of two drugs in the treatment of chronic pulmonary heart disease at acute exacerbation

目的探讨银杏达莫注射液联合低分子肝素钙治疗慢性肺源性心脏病急性加重期的临床疗效。方法 130例患者随机分为两组,均给予常规综合治疗,治疗组加用银杏达莫注射液静滴,每日1次,连用14 d;低分子肝素钙腹部皮下注射,每12 h 1次,疗程7 d。结果治疗组治疗后临床症状改善,血液流变学、心功能分级好转,明显优于对照组。治疗组总有效率92.3%(60/65)优于对照组75.4%(49/65)。结论银杏达莫注射液联合低分子肝素钙治疗慢性肺源性心脏病急性加重期具有安全可靠、见效快、疗程短、毒副作用小等诸多优点,值得临床推广应用。

Objective To explore the clinical curative effect of Yinxingdamo injection and low molecular heparin calcium in the treatment of acute exacerbation of chronic pulmonary heart disease. Methods 130 patients were randomly divided into two groups. All patients were given conventional treatment, and the treatment group was additionally given Yinxingdamo injection by intravenous drip, 1 times a day, for 14 days, and low molecular weight heparin subcutaneous injection, once each 12 hours for 7 days. Results The improvement of clinical symptoms, blood rheology, grade of heart function was more pronounced in the treatment group than in the control group. The to-tal effective rate was 92. 3% in the treatment group （60/65）, which was obviously higher than that in the control group （75. 4%）. Conclusion Yinxingdamo injection combined with low molecular heparin calcium is a safe and quick method in the treatment of acute exacerbation of chronic pulmonary heart disease, with the advantages of short course of treatment, small toxic side effect and other advantages.